NCT00060632View on ClinicalTrials.gov

Safety Study of Ridaforolimus in Patients With Advanced, Refractory or Recurrent Malignancies (MK-8669-001 AM5)(COMPLETED)

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

April 30, 2003

Primary Completion Date

October 31, 2005

Study Completion Date

October 31, 2005

Conditions

TumorsLymphomaMultiple Myeloma

Interventions

DRUG

ridaforolimus

"Administered intravenously once weekly for 4 weeks (1 cycle).~In the absence of disease progression or unacceptable toxicity, patients could continue to receive additional cycles."